LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
2 - 4 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Lavender-top (EDTA) tube
Room temperature; do not separate.
Plasma specimen; anticoagulants other than EDTA; frozen whole blood received; hemolysis
Erythrocyte cholinesterase is measured to diagnose organophosphate and carbamate toxicity and to detect atypical forms of the enzyme. Cholinesterase is irreversibly inhibited by organophosphate insecticides and reversibly inhibited by carbamate insecticides. Serum or plasma pseudocholinesterase is a better measure of acute toxicity, while erythrocyte levels are better for chronic exposure. (Serum level returns to normal prior to normalizing of red cell level).
Values decrease as erythrocytes become senescent.
Spectrophotometry (Ellman) − kinetic
The cholinesterase activity in human red cells is highly but not exclusively specific for acetylcholine. It is referred to as true or specific cholinesterase. Cholinesterase activity present in serum/plasma hydrolyses both choline and aliphatic esters, has a broader range of esterolytic activity, and is referred to as “pseudo-” or “nonspecific” cholinesterase. It hydrolyses acetylcholine only slowly. The systematic name for acetylcholinesterase is acetylcholine acetylhydrolase. Systematic name for cholinesterase (serum/plasma) is acylcholine acylhydrolase. The different nature of the cholinesterases was first described in 1940.1 The plasma enzyme is synthesized by the liver, the red cell enzyme during erythropoiesis.
The enzyme is a large complex protein. There is evidence that it has a multiple subunit structure, four peptide chains that form two dimers. Because of the many constituent amino acids, many molecular variants are possible. The RBC level is increased in hemolytic states such as the thalassemias, spherocytosis, hemoglobin SS, and acquired hemolytic anemias. It is decreased in paroxysmal nocturnal hemoglobinuria and in relapse of megaloblastic anemia. (It returns to normal with therapy.)
Potent inhibitors of cholinesterase may present important clinical toxicological problems. Systemic insecticides (eg, organophosphates or carbamates) are examples. Both RBC acetylcholinesterase and plasma cholinesterase are usually inhibited. The effect on the plasma enzyme is more marked, however, and serum levels are usually used in diagnosis and assessment of recovery. Recovery is best determined by looking for a plateau in erythrocyte cholinesterase activity. Toxic potency may vary, plasma versus red cell cholinesterase, such that in some cases, erythrocyte levels may be needed for diagnosis and/or monitoring. If there is suspicion that a decrease in cholinesterase activity may not relate to the inhibitor effect of an organophosphate, then red cell level of acetylcholinesterase should be obtained. If both serum and RBC levels are significantly decreased, findings are those of exogenous toxic effect.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|007286||Cholinesterase, RBC||2099-0||007286||Cholinesterase, RBC||IU/L||2099-0|
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf